



MOLECULAR TEMPLATES

Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

Jul 9 2021, 8:00 AM EDT

Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 6 2021, 8:00 AM EDT

Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

May 13 2021, 4:30 PM EDT

Stock Overview

| | |
|---------------|------------------|
| Symbol | MTEM |
| Exchange | Nasdaq |
| Market Cap | 397.15m |
| Last Price | \$7.08 |
| 52-Week Range | \$6.41 - \$15.19 |

08/04/2021 04:00 PM EDT

Investor Relations

LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

Management Team

Eric Poma, Ph.D.

Chief Executive Officer & Chief Scientific Officer

Jason Kim

President & Chief Operating Officer

Roger Waltzman, M.D.

Chief Medical Officer

Michael Dowd

Senior Vice President, Project & Alliance Management

Megan Filoon

Vice President, Legal

Ryan Hawkins

Senior Vice President and Head of Manufacturing

Dennis Jones

Senior Vice President, Quality

Sean McLennan

Senior Vice President, Finance and Corporate Controller

Joseph Phillips, Ph.D.

Senior Vice President and Head of CMC Development

Kristen Quigley

Senior Vice President, Clinical Operations

Molecular Templates, Inc.

9301 Amberglen Blvd
Suite 100
Austin, TX 78729

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.